Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J & J Hurries to Fix Plant Issues

By Drug Discovery Trends Editor | May 26, 2010

WASHINGTON (AP) – Johnson & Johnson said it has hired an outside consulting firm to help fix manufacturing problems that triggered a massive recall of children’s medicines and which have drawn ire from federal lawmakers and regulators.

The maker of Tylenol, Motrin and other medications laid out plans to restructure its manufacturing operations in the wake of the latest in a series of recalls that have tarnished the company’s household brands. In a posting to employees on its Web site, J&J’s McNeil Consumer Healthcare unit said it will share its action plan with the Food and Drug Administration by mid-July.

“McNeil is taking steps to bring its operation back to a level of quality that Johnson & Johnson demands of its companies, and that the public rightly expects of us,” reads the statement.

The announcement comes on the same day the FDA ratcheted up scrutiny of J&J, issuing the company a warning letter about lax procedures at a plant that makes sterilization tools.

Colleen Goggins, J&J’s president for consumer products, is scheduled to testify before a House committee on Thursday about a slew of manufacturing problems that triggered the recall of more than 40 medicines last month.

FDA inspectors prodded J&J to recall the children’s medications after discovering the company had not looked into dozens of consumer complaints about “black or dark specks” in Tylenol and other products. FDA’s deputy commissioner is also scheduled to testify Thursday.

J&J, which is based in New Brunswick, N.J., has long enjoyed a sterling corporate image, even ranking first place last year in a poll of company reputations.

That positive image is due in part to J&J’s handling of past product recalls.

The company’s response to a cyanide tampering scare in Chicago that killed seven people in 1982 is considered a textbook example of how to deal with a brand crisis.

J&J had its sales force remove 264,000 Tylenol bottles from Chicago area stores; consumers also were urged to return any Tylenol they had for a safe bottle, and prompt alerts from J&J and the FDA kept the public informed.

But now congressional lawmakers are blasting the company’s competence and integrity.

“It is a moral outrage for a company specifically marketing is products for children to allow a culture of neglect and irresponsibility to taint the medicines that parents and physicians trust to help children get well,” said Rep. Darrell Issa, R-Calif., ranking member on the House Committee on Oversight and Government reform.

On Monday the chairman of the Senate’s health committee issued a letter to the FDA, seeking more information about J&J’s recall.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE